OncoMatch/Clinical Trials/NCT06566443
Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer
Is NCT06566443 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Honokiol for carcinoma, non-small-cell lung.
Treatment: Honokiol — This is a Phase I Trial evaluating the safety of the dietary supplement honokiol for lung cancer chemoprevention. Female or male patients aged 18 years, or older, with early stage lung cancer who have been scheduled for curative surgery will be eligible for participation in the study. The study will only enroll patients with stage I lung cancers less than 4 cm, given the recent approval of neoadjuvant chemotherapy and nivolumab for stage IB tumors \> 4 cm. Approximately, 15 patients will be enrolled in the study. They will take the study drug, honokiol, for 2 weeks prior to the surgery. The primary endpoint will be the Maximum Tolerated Dose (MTD) of honokiol.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage EARLY STAGE
Early stage NSCLC eligible for upfront definitive surgical resection
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Prior chemotherapy ... within 2 weeks prior to trial treatment administration
Cannot have received: targeted small molecule therapy
Prior ... targeted small molecule therapy ... within 2 weeks prior to trial treatment administration
Cannot have received: radiation therapy
Prior ... radiation therapy within 2 weeks prior to trial treatment administration
Cannot have received: agents that target the mitochondrial metabolism
Use of agents that target the mitochondrial metabolism
Cannot have received: investigational agent or device
Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of trial treatment administration
Lab requirements
Blood counts
Hemoglobin ≥9.0 g/dl (without blood transfusion within 2 weeks of laboratory test used to determine eligibility); Absolute neutrophil count ≥1000/μL (without granulocyte colony stimulating factor support within 2 weeks of laboratory test used to determine eligibility); Platelet count ≥100,000/μL (without transfusion within 2 weeks of laboratory test used to determine eligibility)
Kidney function
Creatinine ≤1.5X the ULN or measured creatinine clearance ≥ 60 mL/min/1
Liver function
Serum total bilirubin (TB) ≤1.5 x institutional upper limit of normal (ULN; In the case of known Gilbert's syndrome, a higher serum TB [>1.5 x ULN] is allowed), Aspartate transaminase/alanine transaminase ≤5 x institutional ULN
Adequate organ and marrow function as defined below: Hemoglobin ≥9.0 g/dl (without blood transfusion within 2 weeks of laboratory test used to determine eligibility) Absolute neutrophil count ≥1000/μL (without granulocyte colony stimulating factor support within 2 weeks of laboratory test used to determine eligibility) Platelet count ≥100,000/μL (without transfusion within 2 weeks of laboratory test used to determine eligibility)- Serum total bilirubin (TB) ≤1.5 x institutional upper limit of normal (ULN; In the case of known Gilbert's syndrome, a higher serum TB [>1.5 x ULN] is allowed), Aspartate transaminase/alanine transaminase ≤5 x institutional ULN Creatinine ≤1.5X the ULN or measured creatinine clearance ≥ 60 mL/min/1.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Houston Methodist Neal Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify